奥泰生物、奥浦迈生物、恒瑞医药高管同台探讨：中国何时诞生世界级医药企业？

新浪证券11-13

文/新浪财经上海站陈秀颖　　11月13日，在上海证券交易所国际投资者大会的圆桌论坛上，嘉宾们围绕“中国能否诞生世界级的医药企业？”展开讨论。本场由国泰海通证券研究所副所长余文心主持。　　杭州奥泰生物技术股份有限公司董事长、总经理高飞表示，世界级企业在中国“肯定会出现”。在他看来，行业机会、国际环境、自身创新能力尤其是持续创新力，以及包容协作的团队，是企业走向全球一流的关键。　　上海奥浦迈...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2583562646?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-13 20:07","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2583562646","market":"us","top_or_hot":-1,"title":"奥泰生物、奥浦迈生物、恒瑞医药高管同台探讨：中国何时诞生世界级医药企业？","media":"新浪证券","content":"<div>\n<p>文/新浪财经上海站 陈秀颖\n　　11月13日，在上海证券交易所国际投资者大会的圆桌论坛上，嘉宾们围绕“中国能否诞生世界级的医药企业？”展开讨论。本场由国泰海通证券研究所副所长余文心主持。\n\n　　杭州奥泰生物技术股份有限公司董事长、总经理高飞表示，世界级企业在中国“肯定会出现”。在他看来，行业机会、国际环境、自身创新能力尤其是持续创新力，以及包容协作的团队，是企业走向全球一流的关键。\n　　上海奥浦迈...</p>\n\n<a href=\"https://finance.sina.com.cn/roll/2025-11-13/doc-infxhkcu5227361.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>奥泰生物、奥浦迈生物、恒瑞医药高管同台探讨：中国何时诞生世界级医药企业？</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n奥泰生物、奥浦迈生物、恒瑞医药高管同台探讨：中国何时诞生世界级医药企业？\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-13 20:07 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/roll/2025-11-13/doc-infxhkcu5227361.shtml><strong>新浪证券</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>文/新浪财经上海站 陈秀颖\n　　11月13日，在上海证券交易所国际投资者大会的圆桌论坛上，嘉宾们围绕“中国能否诞生世界级的医药企业？”展开讨论。本场由国泰海通证券研究所副所长余文心主持。\n\n　　杭州奥泰生物技术股份有限公司董事长、总经理高飞表示，世界级企业在中国“肯定会出现”。在他看来，行业机会、国际环境、自身创新能力尤其是持续创新力，以及包容协作的团队，是企业走向全球一流的关键。\n　　上海奥浦迈...</p>\n\n<a href=\"https://finance.sina.com.cn/roll/2025-11-13/doc-infxhkcu5227361.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2097828474.EUR","symbol_name":"AZ EQUITY CHINA \"A\" (EUR) ACC A","start_time":0,"source_url":"https://finance.sina.com.cn/roll/2025-11-13/doc-infxhkcu5227361.shtml","article_id":"2583562646","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583562646","pubTimestamp":1763035620,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"　　11月13日，在上海证券交易所国际投资者大会的圆桌论坛上，嘉宾们围绕“中国能否诞生世界级的医药企业？”　　杭州奥泰生物技术股份有限公司董事长、总经理高飞表示，世界级企业在中国“肯定会出现”。他表示，生物医药企业要在全球产生价值，必须先在中国市场形成价值基础，而国家在政策端的持续支持至关重要。　　现场讨论认为，随着创新能力提升、政策不断完善，中国医药产业未来有望孕育世界级的一流企业。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600276":"恒瑞医药","688293":"奥浦迈","688606":"奥泰生物","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK0183":"MSCI概念","BK0188":"融资融券","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","BK0012":"证金概念","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU0359201612.USD":"贝莱德中国基金A2","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU1997245177.USD":"安联神洲A股基金","BK0028":"国家队","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","BK1191":"制药","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","01276":"恒瑞医药","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","BK0060":"抗癌","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","BK0196":"行业龙头","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","BK0216":"研究试验","LU1146622755.USD":"安本中国A股股票基金A Acc","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","BK0239":"医药制造","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC"},"translate_title":"Executives from Aotai Bio, Opmai Bio, and Hengrui Pharmaceuticals discussed on the same stage: When will a world-class pharmaceutical company be born in China?","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1.5,"688293":1.5,"688606":1.5,"01276":1.5},"content_text":"文/新浪财经上海站 陈秀颖\n　　11月13日，在上海证券交易所国际投资者大会的圆桌论坛上，嘉宾们围绕“中国能否诞生世界级的医药企业？”展开讨论。本场由国泰海通证券研究所副所长余文心主持。\n\n　　杭州奥泰生物技术股份有限公司董事长、总经理高飞表示，世界级企业在中国“肯定会出现”。在他看来，行业机会、国际环境、自身创新能力尤其是持续创新力，以及包容协作的团队，是企业走向全球一流的关键。\n　　上海奥浦迈生物科技股份有限公司董事长肖志华指出，在全球化退潮的时代，中国企业要成为真正的全球化公司挑战更大，但他强调，“一定会出现世界级企业”，中国企业具备突破可能。\n　　江苏恒瑞医药股份有限公司全球研发总裁张连山则强调信心与政策的重要性。他表示，生物医药企业要在全球产生价值，必须先在中国市场形成价值基础，而国家在政策端的持续支持至关重要。\n　　现场讨论认为，随着创新能力提升、政策不断完善，中国医药产业未来有望孕育世界级的一流企业。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：刘万里 SF014","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583562646","isCrawlerRequest":true}